Common inherited mitochondrial DNA mutations and nucleoside reverse transcriptase inhibitor-induced severe hyperlactataemia in HIV-infected adults: an exploratory study

被引:7
作者
Arenas-Pinto, Alejandro [1 ,2 ]
Weller, Ian [1 ]
Ekong, Rosemary [3 ]
Grant, Alison [4 ]
Karstaedt, Alan [5 ]
Reiss, Peter [6 ]
Telisinghe, Lilanganee [7 ]
Weber, Rainer [8 ]
Bolhaar, Martine [5 ]
Bradman, Neil [3 ]
Ingram, Catherine [3 ]
机构
[1] UCL, Ctr Sexual Hlth & HIV Res, London, England
[2] Cent Univ Venezuela, Caracas, Venezuela
[3] UCL, Ctr Genet Anthropol, London, England
[4] London Sch Hyg & Trop Med, London WC1, England
[5] Chris Hani Baragwanath Hosp, Johannesburg, South Africa
[6] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[7] Aurum Inst, Johannesburg, South Africa
[8] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
关键词
ANTIRETROVIRAL THERAPY; PERIPHERAL NEUROPATHY; LACTIC-ACIDOSIS; HAPLOGROUPS; TOXICITY; MECHANISMS; LIPOATROPHY; DISEASE; RISK;
D O I
10.3851/IMP1947
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Genetic predisposition to dideoxynucleoside-induced mitochondrial dysfunction might be related to mitochondrial DNA (mtDNA) polymorphisms. Severe hyperlactataemia is probably the best model to assess such a predisposition. Methods: For this exploratory study in White European and Black African HIV-infected adults, hypervariable region 1 of mtDNA samples from peripheral blood mononuclear cells or buccal smears of patients who have developed confirmed severe hyperlactataemia was sequenced. Additionally, 21 single nucleotide polymorphisms and a 9 bp deletion were genotyped to assign mtDNA haplogroups. Finally, entire mtDNA sequencing was performed in a subset of European samples. Samples were obtained from Black African cases and controls recruited from a single centre in Johannesburg, South Africa and from white European cases from Amsterdam, London and Zurich. Results: A total of 40 cases and 38 controls from Johannesburg were included. All of the cases and 33 controls were receiving stavudine-based therapy at the time of the index date (P= 0.024). The distribution of mtDNA haplotypes was not different between cases and controls (P= 0.137), and neither were the predicted haplogroups (P= 0.751). In total, 11 of the 12 European cases were on stavudine and/or didanosine at the time of the event. No hypervariable region 1 haplotype was consistently found in the European cases. Sequencing of the entire mtDNA from three of these cases supported the absence of any shared mutations other than major alleles frequently seen in the mtDNA database. Conclusions: We did not find an association between homoplasmic inherited mtDNA polymorphisms and severe hyperlactataemia. Our data do not support the existence of non-synonymous mtDNA mutations that explain an increased predisposition to dideoxynucleoside-induced mitochondrial dysfunction.
引用
收藏
页码:275 / 282
页数:8
相关论文
共 24 条
  • [11] Switch From Etravirine Twice Daily to Once Daily in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant HIV-Infected Patients With Suppressed Viremia: The Monetra Study
    Schneider, L.
    Ktorza, N.
    Fourati, S.
    Assoumou, L.
    Courbon, E.
    Caby, F.
    Blanc, C.
    Tindel, M.
    Agher, R.
    Marcelin, A. G.
    Calvez, V.
    Peytavin, G.
    Katlama, C.
    HIV CLINICAL TRIALS, 2012, 13 (05): : 284 - 288
  • [12] Increased Risk of Preterm Delivery Among HIV-Infected Women Randomized to Protease Versus Nucleoside Reverse Transcriptase Inhibitor-Based HAART During Pregnancy
    Powis, Kathleen M.
    Kitch, Douglas
    Ogwu, Anthony
    Hughes, Michael D.
    Lockman, Shahin
    Leidner, Jean
    van Widenfelt, Erik
    Moffat, Claire
    Moyo, Sikhulile
    Makhema, Joseph
    Essex, Max
    Shapiro, Roger L.
    JOURNAL OF INFECTIOUS DISEASES, 2011, 204 (04) : 506 - 514
  • [13] Recovery From Lipodystrophy in HIV-infected Children After Substitution of Stavudine With Zidovudine in a Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy
    Aurpibul, Linda
    Puthanakit, Thanyawee
    Taejaroenkul, Sineenart
    Sirisanthana, Thira
    Sirisanthana, Virat
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (04) : 384 - 388
  • [14] Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors
    Hulgan, Todd
    Donahue, John P.
    Smeaton, Laura
    Pu, Minya
    Wang, Hongying
    Lederman, Michael M.
    Smith, Kimberly
    Valdez, Hernan
    Pilcher, Christopher
    Haas, David W.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (11) : 1081 - 1088
  • [15] Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors
    Todd Hulgan
    John P. Donahue
    Laura Smeaton
    Minya Pu
    Hongying Wang
    Michael M. Lederman
    Kimberly Smith
    Hernan Valdez
    Christopher Pilcher
    David W. Haas
    European Journal of Clinical Pharmacology, 2009, 65 : 1081 - 1088
  • [16] A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children:: The PENTA-4 trial
    Aboulker, JP
    Babiker, A
    Carriere, I
    Darbyshire, JH
    Debré, M
    Giaquinto, C
    Gibb, DM
    Harper, L
    Newberry, A
    Saidi, Y
    Tudor-Williams, G
    AIDS, 1998, 12 (14) : F151 - F160
  • [17] Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study
    Seang, S.
    Fourati, S.
    Keita, Y.
    Blanc, C.
    Tubiana, R.
    Schneider, L.
    Valantin, M. A.
    Caby, F.
    Calin, R.
    Lambert-Niclot, S.
    Marcelin, A. -G.
    Calvez, V.
    Costagliola, D.
    Katlama, C.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (12) : 3356 - 3359
  • [18] Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study
    Nozza, S.
    Galli, L.
    Antinori, A.
    Chiappetta, S.
    Mazzotta, F.
    Zaccarelli, M.
    Ottou, S.
    De Battista, D.
    Pogliaghi, M.
    Di Pietro, M.
    Malnati, M.
    Ripa, M.
    Bonora, S.
    Lazzarin, A.
    Calcagno, Andrea
    Della Torre, Liviana
    Di Perri, Gianni
    Galli, Andrea
    Galli, Laura
    Tambussi, Giuseppe
    Tommasi, Chiara
    CLINICAL MICROBIOLOGY AND INFECTION, 2015, 21 (05) : 510.e1 - 510.e9
  • [19] T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study
    Tincati, Camilla
    Savoldi, Alessia
    Cannizzo, E. Stefania
    Bellistri, Giusi M.
    Termini, Roberta
    Garau, Marzia
    Mancusi, Daniela
    Monforte, Antonella d'Arminio
    Marchetti, Giulia
    ANTIVIRAL THERAPY, 2016, 21 (02) : 133 - 142
  • [20] BMS-986001, an HIV Nucleoside Reverse Transcriptase Inhibitor, Does Not Degrade Mitochondrial DNA in Long-Term Primary Cultures of Cells Isolated from Human Kidney, Muscle, and Adipose Tissue
    Wang, Faye
    Flint, Oliver P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (12) : 6205 - 6212